About The Study: The Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) risk models demonstrated good performance in Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF). Baseline risk did not modify the relative treatment effect of finerenone.

About The Study: In this post hoc analysis, the dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide agonist tirzepatide, compared with the GLP-1 agonist dulaglutide, was associated with a lower incidence of a broad 6-component composite cardiovascular and kidney end point in patients with diabetes and established cardiovascular disease.

First-of-its kind trial results presented by Mount Sinai researcher may help fine-tune treatment protocols

The first randomized trial to test whether adding a small, temporary pump to allow the heart to rest and intentionally delaying percutaneous coronary intervention (PCI), also known as coronary angioplasty, for 30 minutes to reduce heart damage compared with standard immediate PCI in patients with  heart attacks at risk for a large amount of heart damage found no significant difference between the two groups, the study’s primary endpoint. The research was presented at the American College of Cardiology’s Annual Scientific Session (ACC.26).

For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small pouch where blood can pool and form dangerous clots—was comparable to standard medication therapy in reducing the combined rate of all-cause stroke, cardiovascular death and systemic embolism at three years. Moreover, closure of this appendage was found superior to long-term oral anticoagulation for pre-specified major and non-major non-procedural bleeding in these patients, according to research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26).

Patients who had low doses of clot-buster drugs delivered directly to the site of a pulmonary embolism (PE) via a catheter using ultrasound to enhance their effect had significantly better outcomes than those who received standard systemic anticoagulants, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26). The targeted catheter-based approach reduced early PE-related death, circulatory collapse or PE recurrence by more than 60%.

Using the American Heart Association’s recently developed PREVENT score to estimate a patient’s 10-year risk of cardiovascular disease, researchers found that women with the highest risk of cardiovascular disease were most likely to experience osteoporatic bone fractures. The findings could indicate that the PREVENT score may be valuable in identifying patients who could benefit from a bone density screening. 

In 2023, globally 259,000 people died from meningitis and 2.5 million people were infected with the disease, suggests a study published in The Lancet Neurology. Although death and infection rates have declined significantly since 1990, progress is insufficient to meet the WHO targets of a 50% reduction in infections and 70% reduction in deaths by 2030.